Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study

BACKGROUND: Not all non-small cell lung cancer (NSCLC) patients possess drug-targetable driver mutations, and response rates to immune checkpoint blockade therapies also remain unsatisfactory. Therefore, more effective treatments are still needed. Here, we report the results of a phase 2 clinical tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakimi, Kazuhiro, Matsushita, Hirokazu, Masuzawa, Keita, Karasaki, Takahiro, Kobayashi, Yukari, Nagaoka, Koji, Hosoi, Akihiro, Ikemura, Shinnosuke, Kitano, Kentaro, Kawada, Ichiro, Manabe, Tadashi, Takehara, Tomohiro, Ebisudani, Toshiaki, Nagayama, Kazuhiro, Nakamura, Yukio, Suzuki, Ryuji, Yasuda, Hiroyuki, Sato, Masaaki, Soejima, Kenzo, Nakajima, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511646/
https://www.ncbi.nlm.nih.gov/pubmed/32948652
http://dx.doi.org/10.1136/jitc-2020-001185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511646/
https://www.ncbi.nlm.nih.gov/pubmed/32948652
http://dx.doi.org/10.1136/jitc-2020-001185

Ejemplares similares